MLE 4901

Drug Profile

MLE 4901

Alternative Names: AZ 12472520; AZD 2624; AZD 4901; MLE4901

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Millendo Therapeutics
  • Class Small molecules
  • Mechanism of Action Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hot flashes; Polycystic ovary syndrome
  • Discontinued Schizophrenia

Most Recent Events

  • 28 Sep 2017 Millendo Therapeutics terminates a phase II trial for Polycystic ovary syndrome in United Kingdom and USA as the risk/benefit profile no longer indicated continued development (PO) (NCT02865915)
  • 17 Apr 2017 Chemical structure information added
  • 03 Apr 2017 Efficacy and adverse events data from a phase II trial in Hot flashes released by Millendo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top